XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Net Earnings Per Share
9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Net Earnings Per Share Net Earnings Per Share Basic EPS is computed by dividing net earnings available to common stockholders by the weighted average number of common shares outstanding during each period. Diluted EPS is
computed on the basis of the weighted average number of shares of common stock plus the effect of dilutive potential common shares outstanding during the period using the treasury stock method. Dilutive potential common shares include outstanding restricted stock units (“RSUs”) and certain shares underlying the Notes. A reconciliation of the denominators of the basic and diluted EPS calculations follows (in thousands, except per share data):
Three Months Ended
September 30,
Nine Months Ended
September 30,
2022202120222021
Numerator:
Net earnings$57,316 $55,483 $203,131 $157,212 
Denominator:
Weighted average shares used to compute basic EPS34,952 34,855 35,003 35,050 
Dilutive potential common shares due to dilutive RSUs, net of tax effect201 381 243 407 
Dilutive potential common shares due to the Notes1,187 1,509 1,468 1,403 
Weighted average shares used to compute diluted EPS36,340 36,745 36,714 36,860 
Net earnings per share:
Basic$1.64 $1.59 $5.80 $4.49 
Diluted$1.58 $1.51 $5.53 $4.27 
For the three and nine months ended September 30, 2022, 67,000 and 39,000, respectively, of our RSUs were excluded from the diluted EPS calculations and certain potential outstanding shares from the warrants relating to the Call Spread Transactions were excluded from the diluted EPS calculations because their inclusion would have been anti-dilutive. For the three and nine months ended September 30, 2021, 900 and 400, respectively, of our RSUs were excluded from the diluted EPS calculations and certain potential outstanding shares from the warrants related to the Call Spread Transactions were excluded from the diluted EPS calculations because their inclusion would have been anti-dilutive.